PE20211285A1 - Proceso para la produccion de formas farmaceuticas que contienen inhibidores de los canales task-1 y task-3 y su uso para la terapia de trastornos respiratorios - Google Patents
Proceso para la produccion de formas farmaceuticas que contienen inhibidores de los canales task-1 y task-3 y su uso para la terapia de trastornos respiratoriosInfo
- Publication number
- PE20211285A1 PE20211285A1 PE2021000753A PE2021000753A PE20211285A1 PE 20211285 A1 PE20211285 A1 PE 20211285A1 PE 2021000753 A PE2021000753 A PE 2021000753A PE 2021000753 A PE2021000753 A PE 2021000753A PE 20211285 A1 PE20211285 A1 PE 20211285A1
- Authority
- PE
- Peru
- Prior art keywords
- task
- respiratory disorders
- production
- therapy
- channels
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Otolaryngology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente solicitud se refiere a un procedimiento para la produccion de formulaciones farmaceuticas estables, caracterizado porque en una primera etapa se introduce al menos un ester de acido graso de polioxietilensorbitano como solubilizante y/o PEG 400 como codisolvente, en el mismo se diluyen al menos un antioxidante y una cantidad terapeuticamente eficaz de al menos un inhibidor del canal TASK-1 y/o TASK-3, seleccionado de (3-cloro-6-metoxipiridin-2-il)(3-{[2-(4-isopropilfenil)imidazo[1,2-a]pirimidin-3-il]metil}-3,8- diazabiciclo[3.2.1]oct-8-il)metanona o una sal farmaceuticamente aceptable y luego se anaden al menos un regulador de pH, agua y opcionalmente glicerol, ester de acido graso de polioxietilensorbitano o PEG400 y opcionalmente al menos un edulcorante y el valor del pH de la solucion resultante esta entre 6,8 y 8,2. Dichas formulaciones son utiles para el tratamiento y/o la prevencion de trastornos respiratorios que incluyen trastornos respiratorios relacionados con el sueno, como apneas obstructivas y centrales del sueno y ronquidos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18208601 | 2018-11-27 | ||
| PCT/EP2019/081950 WO2020109109A1 (de) | 2018-11-27 | 2019-11-20 | Verfahren zur herstellung von pharmazeutischen darreichungsformen enthaltend inhibitoren von task-1 und task-3 kanälen und deren verwendung für die therapie von atemstörungen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20211285A1 true PE20211285A1 (es) | 2021-07-19 |
Family
ID=64500266
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2021000753A PE20211285A1 (es) | 2018-11-27 | 2019-11-20 | Proceso para la produccion de formas farmaceuticas que contienen inhibidores de los canales task-1 y task-3 y su uso para la terapia de trastornos respiratorios |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US20210393624A1 (es) |
| EP (1) | EP3886806A1 (es) |
| JP (1) | JP7474760B2 (es) |
| KR (1) | KR20210095898A (es) |
| CN (2) | CN119258012A (es) |
| AU (1) | AU2019389215A1 (es) |
| BR (1) | BR112021008153A2 (es) |
| CA (1) | CA3120775A1 (es) |
| CL (1) | CL2021001359A1 (es) |
| CO (1) | CO2021006814A2 (es) |
| CR (1) | CR20210277A (es) |
| DO (1) | DOP2021000105A (es) |
| EA (1) | EA202191480A1 (es) |
| EC (1) | ECSP21036326A (es) |
| GE (1) | GEP20247606B (es) |
| IL (1) | IL283324A (es) |
| JO (1) | JOP20210121A1 (es) |
| MA (1) | MA54275A (es) |
| MX (1) | MX2021006081A (es) |
| PE (1) | PE20211285A1 (es) |
| PH (1) | PH12021551186A1 (es) |
| SA (1) | SA521422114B1 (es) |
| SG (1) | SG11202105551YA (es) |
| WO (1) | WO2020109109A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190284A1 (ar) | 2017-06-14 | 2019-12-11 | Bayer Pharma AG | مركبات إيميدازوبيريميدين مستبدلة بديازا ثنائي الحلقة واستخدامها للمعالجة من اضطرابات التنفس |
| WO2023118102A1 (en) * | 2021-12-22 | 2023-06-29 | Bayer Aktiengesellschaft | Combination of a task1/3 channel blocker with a muscarinic receptor antagonist for the treatment of sleep apnea |
| AU2023232173A1 (en) * | 2022-03-11 | 2024-10-17 | Loma Linda University | Compositions and methods of treatment of disease using combination of a nitrodilator and a nitrogen oxide compound |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19834047A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
| DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
| DE19943634A1 (de) | 1999-09-13 | 2001-04-12 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE19943636A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE19943635A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE19943639A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften |
| AR031176A1 (es) | 2000-11-22 | 2003-09-10 | Bayer Ag | Nuevos derivados de pirazolpiridina sustituidos con piridina |
| DE10110749A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Substituierte Aminodicarbonsäurederivate |
| DE10110750A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
| WO2006128288A1 (en) * | 2005-06-02 | 2006-12-07 | Thallion Pharmaceuticals Inc. | Formulation comprising farnesyl dibenzodiazepinone and a pharmaceutically acceptable surfactant |
| WO2007124849A2 (en) * | 2006-04-27 | 2007-11-08 | Sanofi-Aventis Deutschland Gmbh | Inhibitors of the task-1 and task-3 ion channel |
| WO2009114118A2 (en) * | 2008-03-08 | 2009-09-17 | Theraquest Biosciences, Inc. | Oral pharmaceutical compositions of buprenorphine and method of use |
| WO2011106276A1 (en) * | 2010-02-25 | 2011-09-01 | Merck Sharp & Dohme Corp. | Task channel antagonists |
| DE102010021637A1 (de) | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung |
| AU2011275825A1 (en) | 2010-07-09 | 2013-02-07 | Bayer Intellectual Property Gmbh | Ring-fused pyrimidines and triazines and use thereof for the treatment and/or prophylaxis of cardiovascular diseases |
| US9132243B2 (en) | 2010-07-23 | 2015-09-15 | Tannermedico A/S | Method of administering a substance to the throat |
| DE102010040233A1 (de) | 2010-09-03 | 2012-03-08 | Bayer Schering Pharma Aktiengesellschaft | Bicyclische Aza-Heterocyclen und ihre Verwendung |
| DE102010043379A1 (de) | 2010-11-04 | 2012-05-10 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung |
| JP2018522854A (ja) * | 2015-06-22 | 2018-08-16 | リポカイン インコーポレーテッド | １７−ヒドロキシプロゲステロンエステル含有経口組成物及び関連方法 |
| JP2018536693A (ja) | 2015-12-10 | 2018-12-13 | バイエル・ファルマ・アクティエンゲゼルシャフト | 睡眠関連呼吸障害を治療するためのＴＡＳＫ−１およびＴＡＳＫ−２チャネルの遮断薬としての２−フェニル−３−（ピペラジノメチル）イミダゾ［１，２−ａ］ピリジン誘導体 |
| WO2017097671A1 (de) | 2015-12-10 | 2017-06-15 | Bayer Pharma Aktiengesellschaft | Substituierte perhydropyrrolo[3,4-c]pyrrol-derivate und ihre verwendung |
| JOP20190005A1 (ar) | 2016-07-20 | 2019-01-20 | Bayer Ag | مركبات ديازاهيترو ثنائية الحلقة مستبدلة واستخداماتها |
| EP3338764A1 (de) * | 2016-12-21 | 2018-06-27 | Bayer Pharma Aktiengesellschaft | Pharmazeutische darreichungsformen enthaltend inhibitoren von task-1 und task-3 kanälen und deren verwendung für die therapie von atemstörungen |
| JOP20190141A1 (ar) | 2016-12-21 | 2019-06-12 | Bayer Pharma AG | أشكال جرعات صيدلية تحتوي على مثبطات لقناة task-1 و task-3 واستخدامها في معالجة اضطراب تنفسي |
| JOP20190148A1 (ar) | 2016-12-21 | 2019-06-18 | Bayer Pharma AG | أشكال جرعات صيدلية تحتوي على مثبطات قنوات task-1 و task-3 واستخدامها لمعالجة الاضطرابات التنفسية |
-
2019
- 2019-11-20 EA EA202191480A patent/EA202191480A1/ru unknown
- 2019-11-20 EP EP19805677.2A patent/EP3886806A1/de active Pending
- 2019-11-20 PE PE2021000753A patent/PE20211285A1/es unknown
- 2019-11-20 MA MA054275A patent/MA54275A/fr unknown
- 2019-11-20 CN CN202410784376.XA patent/CN119258012A/zh active Pending
- 2019-11-20 SG SG11202105551YA patent/SG11202105551YA/en unknown
- 2019-11-20 JO JOP/2021/0121A patent/JOP20210121A1/ar unknown
- 2019-11-20 MX MX2021006081A patent/MX2021006081A/es unknown
- 2019-11-20 CA CA3120775A patent/CA3120775A1/en active Pending
- 2019-11-20 KR KR1020217019408A patent/KR20210095898A/ko active Pending
- 2019-11-20 JP JP2021529444A patent/JP7474760B2/ja active Active
- 2019-11-20 CN CN201980077910.0A patent/CN113194924B/zh active Active
- 2019-11-20 US US17/296,914 patent/US20210393624A1/en active Pending
- 2019-11-20 GE GEAP201915674A patent/GEP20247606B/en unknown
- 2019-11-20 CR CR20210277A patent/CR20210277A/es unknown
- 2019-11-20 WO PCT/EP2019/081950 patent/WO2020109109A1/de active Application Filing
- 2019-11-20 AU AU2019389215A patent/AU2019389215A1/en active Pending
- 2019-11-20 BR BR112021008153-4A patent/BR112021008153A2/pt unknown
-
2021
- 2021-05-20 IL IL283324A patent/IL283324A/en unknown
- 2021-05-21 EC ECSENADI202136326A patent/ECSP21036326A/es unknown
- 2021-05-24 PH PH12021551186A patent/PH12021551186A1/en unknown
- 2021-05-24 CO CONC2021/0006814A patent/CO2021006814A2/es unknown
- 2021-05-25 CL CL2021001359A patent/CL2021001359A1/es unknown
- 2021-05-26 SA SA521422114A patent/SA521422114B1/ar unknown
- 2021-05-27 DO DO2021000105A patent/DOP2021000105A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PH12021551186A1 (en) | 2021-11-03 |
| CO2021006814A2 (es) | 2021-06-10 |
| CN113194924B (zh) | 2024-07-12 |
| SA521422114B1 (ar) | 2023-12-21 |
| CN113194924A (zh) | 2021-07-30 |
| DOP2021000105A (es) | 2021-07-22 |
| AU2019389215A1 (en) | 2021-06-10 |
| EA202191480A1 (ru) | 2021-08-27 |
| MA54275A (fr) | 2022-03-02 |
| EP3886806A1 (de) | 2021-10-06 |
| JP2022508217A (ja) | 2022-01-19 |
| ECSP21036326A (es) | 2021-06-30 |
| MX2021006081A (es) | 2021-07-06 |
| CR20210277A (es) | 2021-07-07 |
| JOP20210121A1 (ar) | 2023-01-30 |
| WO2020109109A1 (de) | 2020-06-04 |
| IL283324A (en) | 2021-07-29 |
| SG11202105551YA (en) | 2021-06-29 |
| JP7474760B2 (ja) | 2024-04-25 |
| BR112021008153A2 (pt) | 2021-08-03 |
| KR20210095898A (ko) | 2021-08-03 |
| US20210393624A1 (en) | 2021-12-23 |
| GEP20247606B (en) | 2024-03-11 |
| CN119258012A (zh) | 2025-01-07 |
| CA3120775A1 (en) | 2020-06-04 |
| CL2021001359A1 (es) | 2021-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20211285A1 (es) | Proceso para la produccion de formas farmaceuticas que contienen inhibidores de los canales task-1 y task-3 y su uso para la terapia de trastornos respiratorios | |
| CO2022001094A2 (es) | Pirrolo[2,3-b]pirazinas como inhibidores de hpk1 y uso de las mismas | |
| RU2018119295A (ru) | Фармацевтические составы для местного применения для лечения связанных с воспалением состояний | |
| CL2020003131A1 (es) | Compuestos de purinona y su uso en el tratamiento del cáncer | |
| MX2022010520A (es) | Macrociclos peptidicos contra acinetobacter baumannii. | |
| MX388781B (es) | Compuestos de quinazolina sustituido y su uso como inhibidores de proteínas kras, hras y/o nras mutantes g12c. | |
| CR20190483A (es) | Compuestos de heteroarilo bicíclicos 6-6 fusionados y su uso como inhibidores de lats | |
| CR20150628A (es) | Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades | |
| DOP2013000105A (es) | Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a la angiogénesis | |
| CY1106107T1 (el) | Φαρμακολογικες μορφοποιησεις που πepιλαμβανουν ρεσβepατρολη και χρηση αυτων | |
| CL2020002562A1 (es) | (divisional de solicitud 1097-2020) derivados de piridincarbonilo y usos terapéuticos de los mismos como inhibidores de trpc6. | |
| CO4950524A1 (es) | Inhibidores de acido nitrico sintasa | |
| AU2018236805B2 (en) | Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives | |
| CO2018004933A2 (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer | |
| MX2019006881A (es) | Composicion farmaceutica que comprende derivados de glutarimida y uso de los mismos en el tratamiento de enfermedades eosinofilicas. | |
| ITBO20110012A1 (it) | Composizioni farmaceutiche comprendenti rifaximina e loro uso. | |
| BR112015029401A2 (pt) | derivados pirazolo-pirrolidin-4-ona e seu uso no tratamento de doenças | |
| PH12019502150A1 (en) | Compounds and methods for the treatment of parasitic diseases | |
| PE20191240A1 (es) | Formas de administracion farmaceutica que contienen inhibidores de canales task-1 y task-3 y su uso para el tratamiento de trastornos respiratorios | |
| EA200870469A1 (ru) | Новые, содержащие нимесулид, фармацевтические композиции с низкой дозой, их получение и применение | |
| PE20120788A1 (es) | Composiciones farmaceuticas para el tratamiento del cancer y otras enfermedades o trastornos | |
| MX2020003993A (es) | Derivados de bencimidazol y sus usos. | |
| AR043822A1 (es) | Formas de dosificacion y procedimientos de tratamiento que usan inhibidores del vegfr | |
| ECSP19026973A (es) | Derivados de naftiridinona y su uso en el tratamiento de la arritmia | |
| MX2019006612A (es) | Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta (pi3kdelta). |